| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/04/2013 | US20130171271 Compositions and Methods for Enhancing the Effectiveness of Systemic, HIPEC, IP, and Related Cancer Treatments |
| 07/04/2013 | US20130171269 Compositions and methods for alleviating symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder |
| 07/04/2013 | US20130171268 Methods and compositions for treatment of mitochondrial toxicity |
| 07/04/2013 | US20130171267 Topical formulations for the prevention of sexually transmitted disease and methods of producing the same |
| 07/04/2013 | US20130171257 Extended release opioid abuse deterrent compositions and methods of making same |
| 07/04/2013 | US20130171256 Alcohol-resistant extended release dosage forms comprising venlafaxine |
| 07/04/2013 | US20130171254 Fast dissolving pharmaceutical composition comprising lornoxicam |
| 07/04/2013 | US20130171250 Methods of treating hypertriglyceridemia |
| 07/04/2013 | US20130171249 Methods of treating hypertriglyceridemia |
| 07/04/2013 | US20130171243 Octreotide-modified nanomedicine for cancer treatment or cancer palliative care |
| 07/04/2013 | US20130171241 Liposomes with lipids having an advantageous pka-value for rna delivery |
| 07/04/2013 | US20130171240 Drug carrier and drug carrier kit for inhibiting fibrosis |
| 07/04/2013 | US20130171239 Methods and compositions for the treatment of infections |
| 07/04/2013 | US20130171237 Aripiprazole compositions and methods for its transdermal delivery |
| 07/04/2013 | US20130171236 Prevention and Treatment of Ischemia-Reperfusion Injury and Related Conditions |
| 07/04/2013 | US20130171230 Reconstituted nut and/or carob ingredient |
| 07/04/2013 | US20130171229 Implantable polymeric device for sustained release of buprenorphine |
| 07/04/2013 | US20130171223 Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients and supression of crystallization of pharmaceutical active incredients |
| 07/04/2013 | US20130171214 Pharmaceutical Compositions |
| 07/04/2013 | US20130171210 Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
| 07/04/2013 | US20130171209 Reducing post-operative adhesion formation with intraperitoneal glutamine |
| 07/04/2013 | US20130171207 Micelle encapsulation of a combination of therapeutic agents |
| 07/04/2013 | US20130171205 Nanocell Drug Delivery System |
| 07/04/2013 | US20130171201 Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions |
| 07/04/2013 | US20130171200 Heat Patch for Diabetes |
| 07/04/2013 | US20130171198 Antimicrobial and vulnerary action pharmaceutical composition for external application and its production process |
| 07/04/2013 | US20130171196 Immunomodulatory Compounds for the Restoration of Vitamin D Sensitivity in Vitamin D Resistant Tumor Cells |
| 07/04/2013 | US20130171194 STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS |
| 07/04/2013 | US20130171193 Therapeutic vaccination against active tuberculosis |
| 07/04/2013 | US20130171187 Glucan-based vaccines |
| 07/04/2013 | US20130171173 Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf |
| 07/04/2013 | US20130171172 Calpain-3 inhibitors for treating muscular dystrophies and cardiomyopathies |
| 07/04/2013 | US20130171171 Prostaglandin transporter inhibitors |
| 07/04/2013 | US20130171163 Inhibition of LAR Phosphatase to Enhance Therapeutic Angiogenesis |
| 07/04/2013 | US20130171162 Compositions and methods for the prevention of oxidative degradation of proteins |
| 07/04/2013 | US20130171161 Method and composition for the treatment of diseases caused by or associated with hiv |
| 07/04/2013 | US20130171158 Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1 |
| 07/04/2013 | US20130171151 Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| 07/04/2013 | US20130171145 Methods of treating liver disease |
| 07/04/2013 | US20130171141 Combination of hdac inhibitors with thrombocytopenia drugs |
| 07/04/2013 | US20130171139 Ncam-vase and neurodegeneration |
| 07/04/2013 | US20130171135 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| 07/04/2013 | US20130171133 Cancer methods |
| 07/04/2013 | US20130171127 Composition for regenerating normal tissue from fibrotic tissue |
| 07/04/2013 | US20130171120 Composition for enhancing physical performance |
| 07/04/2013 | US20130171106 Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
| 07/04/2013 | US20130171105 Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor |
| 07/04/2013 | US20130171104 Synergistic activity of modulators of the no metabolism and of nadph oxidase in the sensitization of tumor cells |
| 07/04/2013 | US20130171103 Methods for treating viral conditions |
| 07/04/2013 | US20130171102 Heterocyclic flaviviridae virus inhibitors |
| 07/04/2013 | US20130171101 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections |
| 07/04/2013 | US20130171098 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors |
| 07/04/2013 | US20130171097 Method for the prophylactic or therapeutic treatment of glucocorticoid-induced osteoporosis |
| 07/04/2013 | US20130171096 Immunobinders directed against sclerostin |
| 07/04/2013 | US20130171094 Use of vanadium compounds to accelerate bone healing |
| 07/04/2013 | US20130171092 Alpha-cyanoacrylate ester synthesis |
| 07/04/2013 | US20130171091 Nanocell Drug Delivery System |
| 07/04/2013 | US20130171090 Methods of treating hepatic encephalopathy |
| 07/04/2013 | US20130171089 Topical formulations for the prevention of sexually transmitted disease and methods of producing the same |
| 07/04/2013 | US20130171079 Composition to stabilise kojic acid |
| 07/04/2013 | US20130171077 Ion channel modulating compounds and uses thereof |
| 07/04/2013 | US20130171073 Treatment of pituitary corticotroph tumors using r-roscovitine |
| 07/04/2013 | US20130171069 Neurotoxic target for amylospheroid, method and material for reducing the neurotoxicity of amylospheroid, and use thereof |
| 07/04/2013 | US20130167859 Methods for making up a keratinous substrate |
| 07/04/2013 | US20130167838 Nasal formulation |
| 07/04/2013 | DE112010005848T5 Amidverbindungen Amide compounds |
| 07/04/2013 | DE102012005452A1 Zusammensetzung für die nasale Applikation mit verbesserter Stabilität A composition for nasal administration having improved stability |
| 07/04/2013 | DE102007061630B4 Neue Verbindungen und Herstellung von Montelukast-Natrium New connections and preparation of montelukast sodium |
| 07/04/2013 | CA2861247A1 Antisense nucleic acids |
| 07/04/2013 | CA2861202A1 Novel nicotinamide derivative or salt thereof |
| 07/04/2013 | CA2861013A1 New azetidine derivatives, pharmaceutical compositions and uses thereof |
| 07/04/2013 | CA2858565A1 Methods of identifying and using mdm2 inhibitors |
| 07/04/2013 | CA2858285A1 1,3-diphenylpropane derivatives, preparations and uses thereof |
| 07/04/2013 | CA2857347A1 Composition and method for compounded therapy |
| 07/04/2013 | CA2857339A1 Solid compositions comprising an hcv inhibitor |
| 07/04/2013 | CA2857043A1 Silicone-based composition for skin treatment |
| 07/04/2013 | CA2856347A1 Fused tricyclic compounds as raf kinase inhibitors |
| 07/04/2013 | CA2856309A1 Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
| 07/04/2013 | CA2855919A1 Diphenylmethyl piperazine derivative and pharmaceutical composition using same |
| 07/04/2013 | CA2854281A1 A muscle atrophy inhibitor |
| 07/04/2013 | CA2832465A1 Methods and compositions for treating parkinson's disease |
| 07/04/2013 | CA2806706A1 Dexmedetomidine premix formulation |
| 07/03/2013 | EP2610620A1 Histone deacetylase 10-inhibitor co-treatment in cancer |
| 07/03/2013 | EP2610264A2 N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production |
| 07/03/2013 | EP2610263A1 Sialic acid dimers |
| 07/03/2013 | EP2610260A1 Crystal of tricyclic pyrazolopyrimidine derivative |
| 07/03/2013 | EP2610259A1 Free crystal of tricyclic pyrazolopyrimidine derivative |
| 07/03/2013 | EP2610258A1 Substituted piperidino dihydrothieno pyrimidines |
| 07/03/2013 | EP2610257A1 Diimidated derivative of berbamine, and preparation method therefor and use thereof |
| 07/03/2013 | EP2610256A1 Pyrimidine derivatives as protein kinase inhibitors |
| 07/03/2013 | EP2610255A2 Novel heterocyclic compound, and composition for treating inflammatory diseases using same |
| 07/03/2013 | EP2610254A1 Deuterated benzoquinoline derivatives as inhibitors of vesicular monoamine transporter 2 |
| 07/03/2013 | EP2610251A1 Novel polymorphic forms of dabigatran etexilate and process for the preparation thereof |
| 07/03/2013 | EP2610249A1 Pluripotent stem cell cardiomyocyte differentiation-promoting agent |
| 07/03/2013 | EP2610248A1 Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using a palladium compound |
| 07/03/2013 | EP2610247A1 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists |
| 07/03/2013 | EP2610246A1 Ethanamine compounds and methods of using the same |
| 07/03/2013 | EP2610245A1 Pipecolate-sulfonamides for treatment of psychiatric disorders |
| 07/03/2013 | EP2610244A1 Indole compounds |
| 07/03/2013 | EP2610242A1 Positively charged water-soluble prodrugs of aspirin |